TQFL19, a Novel Derivative of Thymoquinone (TQ), Plays an Essential Role by Inhibiting Cell Growth, Metastasis, and Invasion in Triple-Negative Breast Cancer
Molecules · 2025
DOI: 10.3390/molecules30040773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Ali El-Far und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Benzoquinones, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Program, Luzhou Science and Technology Project.
Abstract (Originalsprache)
Breast cancer (BC) is a significant public health concern globally. Triple-negative breast cancer (TNBC) is considered the most challenging type, as it is defined by an absence of estrogen and progesterone receptor expression, along with a lack of HER2 overexpression. In the current study, we developed a novel thymoquinone (TQ), TQFL19, to control TNBC progression.
Purpose
The current study aimed to investigate the anticancer potential of a newly synthesized TQFL19 against TNBC. Study design: To achieve our research goals, we meticulously developed both in vitro and in vivo studies focused on TNBC cell growth, metastasis, and invasion.
Results
Characterization and ADMET properties prediction of TQFL19 were first performed before treating TNBC cells. TQFL19 exhibited more potent cytotoxicity than TQ against 4T1, BT-549, and MDA-MB-231 cells and induced apoptosis of 4T1 and MDA-MB-231, besides cell cycle arrest of MDA-MB-231. In vivo mice allograft of 4T1 revealed the ability of TQFL19 to hinder the growth, migration, and metastasis of TNBC cells.
Conclusions
The results suggest that TQFL19 potentially inhibited TNBC growth, metastasis, and invasion. The results conclude that TQFL19 could be a viable candidate for TNBC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, China.
- Department of Chemistry, Southwest Medical University, Luzhou 646000, China.
- School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
- Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha 410013, China.
ORCID-Profile: Ali El-Far, Jingliang Cheng, Junjiang Fu
Förderung
- National Natural Science Foundation of China
- Sichuan Science and Technology Program
- Luzhou Science and Technology Project
Zitieren
APA
El-Far, A., Liu, X., Xiao, T., Du, J., Du, X., Wei, C., Cheng, J., Zou, H., & Fu, J. (2025). TQFL19, a Novel Derivative of Thymoquinone (TQ), Plays an Essential Role by Inhibiting Cell Growth, Metastasis, and Invasion in Triple-Negative Breast Cancer. Molecules. https://doi.org/10.3390/molecules30040773
Vancouver
El-Far A, Liu X, Xiao T, Du J, Du X, Wei C, et al. TQFL19, a Novel Derivative of Thymoquinone (TQ), Plays an Essential Role by Inhibiting Cell Growth, Metastasis, and Invasion in Triple-Negative Breast Cancer. Molecules. 2025. doi:10.3390/molecules30040773
BibTeX
@article{ElFar2025,
author = {El-Far, Ali and Liu, Xiaoyan and Xiao, Ting and Du, Jun and Du, Xinwei and Wei, Chunli and Cheng, Jingliang and Zou, Hui and Fu, Junjiang},
title = {TQFL19, a Novel Derivative of Thymoquinone (TQ), Plays an Essential Role by Inhibiting Cell Growth, Metastasis, and Invasion in Triple-Negative Breast Cancer},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30040773}
}
EUVIMED